A Randomized, Double-blind, Active Control Evaluation of the Safety of BioErodible MucoAdhesive (BEMA) Buprenorphine NX for Buprenorphine Induction of Opioid Dependent Subjects
Withdrawn prior to enrolment
Phase of Trial: Phase III
Latest Information Update: 09 May 2017
At a glance
- Drugs Buprenorphine/naloxone (Primary) ; Buprenorphine
- Indications Opioid abuse
- Focus Therapeutic Use
- Sponsors BioDelivery Sciences International
- 02 May 2017 Planned End Date changed from 1 Dec 2015 to 1 May 2017.
- 02 May 2017 Planned primary completion date changed from 1 Dec 2015 to 1 May 2017.
- 02 May 2017 Status changed from not yet recruiting to withdrawn prior to enrolment.